Related Experiment Videos
Growth and development of children born to patients after cancer therapy
Insights
Children born to parents undergoing chemotherapy face higher risks of health complications, including failure to thrive. Conception during active cancer treatment poses significant risks, necessitating further research for improved patient counseling.
Area of Science:
- Pediatric Health
- Oncology
- Reproductive Medicine
Background:
- Cancer treatments like chemotherapy and radiotherapy can impact reproductive health.
- Concerns exist regarding the potential effects of parental cancer treatment on offspring.
- Limited data is available on the long-term health outcomes of children conceived during or after parental cancer therapy.
Purpose of the Study:
- To evaluate the physical health, growth, and development of children born to parents who received chemotherapy or radiotherapy.
- To assess the immunologic and hematologic status of these children.
- To identify potential risks associated with conception during or after parental cancer treatment.
Main Methods:
- Retrospective study of 18 children born to parents with a history of chemotherapy or radiotherapy.
- Detailed medical history, physical examinations, and documentation of parental treatment.
- Evaluation of children's physical health, growth, development, immune function, and hematologic status.
Main Results:
- Children born to parents on active chemotherapy showed a higher incidence of failure to thrive (3 out of 4).
- One child born during parental treatment had congenital abnormalities and trisomy 13-15, with early mortality.
- Children conceived after parental treatment had a lower rate of complications, though some exhibited growth concerns.
Conclusions:
- Procreation while undergoing chemotherapy is associated with a significant risk of adverse outcomes in children.
- Further research is crucial to establish comprehensive guidelines for counseling cancer patients regarding fertility and pregnancy.
- The findings underscore the importance of discussing reproductive risks with patients undergoing cancer therapy.
Abstract:
Eighteen children born to parents who had previously received chemotherapy or radiotherapy were examined for physical health, growth, and development. The immunologic and the hematologic status of these children was also evaluated. Their ages ranged from birth to 15 years. The children had a careful history and physical examination to detect any abnormal symptoms or signs, and the parent's previous treatment was carefully documented. Four sets of parents had children while one of the parents was on active treatment (2 male and 2 female). Of the male patients, one patient's wife had a baby that was "small for gestational age" at birth and had transient failure to thrive; the other child was normal. Of the female patients, one offspring was small for gestational age at birth and the other was normal, but both continued to have failure to thrive for up to 17 months and 26 months, respectively. Ten parents procreated after being treated with chemotherapy and/or radiotherapy, to whom 14 children were born. One child was a stillbirth with multiple congenital abnormalities, and another child had trisomy 13-15 and died 6 months later. The other 12 children were normal at birth, but one child is under the 5th percentile for growth at twelve months of age. In all children studied, immune function test, complete blood count, and viral titers were considered normal for age. In our study, we found that three out of four children born to parents who were on chemotherapy had failure to thrive. Of the 14 children born to parents who conceived after being off chemotherapy, 11 were found to be normal in growth and development. These results imply that there is a high risk of complications in children born to parents who procreated while receiving chemotherapy. Further studies are needed to develop better guidelines for counseling cancer patients who want to have children.